Descrizione del progetto
Uno sguardo più attento ai rischi per la salute post-COVID
La fase post-acuta della COVID-19 rappresenta un rischio allarmante per le malattie non trasmissibili, indipendentemente dalla gravità della fase acuta. Con una riduzione della funzionalità degli organi fino al 70% dei pazienti in questa fase, gli oltre 183 milioni di casi segnalati nell’UE potrebbero portare a un’impennata delle malattie non trasmissibili. In quest’ottica, il progetto POINT, finanziato dall’UE, sta sperimentando un approccio completo per mitigare in modo efficace i rischi legati alla fase post-acuta. In particolare, sta sviluppando biomarcatori, un modello di gemelli virtuali per il supporto clinico e linee guida rivolte ai gruppi vulnerabili. Grazie a un consorzio interdisciplinare e a vaste coorti europee, POINT promette di rivoluzionare l’assistenza sanitaria post-COVID, anticipando le sfide future delle malattie infettive.
Obiettivo
The post-acute phase (PAP) of COVID-19, occurring ≥4 months after the acute phase, is associated with an increased risk for the development of non-communicable diseases (NCDs). The risk of complications in this phase does not depend on the severity of the acute phase. In the EU, more than 183 million cases of COVID-19 have been reported and up to 70% of patients suffer reduced organ function in the PAP. Our conservative estimate it that 5% of people who have suffered COVID-19 are at risk of developing NCDs of the pulmonary, cardiovascular and renal systems due to the PAP.
To avoid the significant socioeconomic costs related to this burden, POINT will develop knowledge-based biomarkers for prevention and management of NCDs, a virtual twin model that offers clinical decision support, and clinical guidelines and recommendations for the entire health care value chain with special attention to vulnerable groups. We will fulfil an unmet need for knowledge and tools to minimize the risk factors of the PAP at the optimal point in time, when healthcare systems will have to redirect their focus from the acute phase of COVID-19 to the post-acute phase. The outcomes of POINT will aid the health care value chain already from an early phase of the project. Furthermore, POINT will correlate and promote knowledge on the development of NCDs in general and the risks of PAP from other infectious diseases.
POINT will meet the challenges with a holistic approach from a truly interdisciplinary consortium consisting of clinical experts, molecular biologists, behavioural scientists, and computer scientists, who will take advantage of cohorts of more than 6 million Europeans, and cross-sectional biobanks from more than 6000 Europeans. Researchers will work together with standardisation experts, an end-user organization representing >120.000 physicians, as well as a dedicated partner for data management ensuring rapid absorption of the outcomes of the project by all stakeholders.
Campo scientifico
Parole chiave
Programma(i)
Argomento(i)
Meccanismo di finanziamento
HORIZON-RIA - HORIZON Research and Innovation ActionsCoordinatore
1165 Kobenhavn
Danimarca